Patents by Inventor Bruce McCreedy

Bruce McCreedy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240327482
    Abstract: Compositions and methods for making and using therapeutic agents comprising myeloid cell specific engagers, used for immunotherapy of cancer or infection.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240252630
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 1, 2024
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11944680
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: January 18, 2023
    Date of Patent: April 2, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • NANOPARTICLE COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20240066120
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Application
    Filed: October 20, 2022
    Publication date: February 29, 2024
    Inventor: Bruce MCCREEDY
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230277659
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: January 18, 2023
    Publication date: September 7, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, JR.
  • Compositions and methods for immunotherapy
    Patent number: 11712477
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: August 1, 2023
    Assignee: NexImmune, Inc.
    Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11628218
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: April 18, 2023
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • Nanoparticle compositions and methods for immunotherapy
    Patent number: 11510981
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 29, 2022
    Assignee: NexImmune, Inc.
    Inventor: Bruce McCreedy
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220152199
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Inventors: Daniel GETTS, Yuxiao Wang, Bruce McCreedy, JR.
  • METHODS OF INHIBITING LYSINE-SPECIFIC DEMETHYLASE 1 (LSD-1)
    Publication number: 20220047528
    Abstract: Methods of inhibiting LSD1 activity by administering a compound that binds to SWIRM domain of LSD1 and inhibits LSD1 activity; methods of inhibiting LSD1 activity where the compound interacts with L547 residue within the hydrophobic pocket of LSD1; methods of determining the efficacy of a drug to be an LSD1 inhibitor wherein a candidate drug is screened to determine whether it binds to SWIRM domain of LSD1 and inhibits LSD1 activity.
    Type: Application
    Filed: July 26, 2021
    Publication date: February 17, 2022
    Inventors: Shawn Blumberg, Jonathan Bohmann, Aundrietta D. Duncan, Stephen Horrigan, Bruce McCreedy, Daniela Santiesteban
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20200345855
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Application
    Filed: March 17, 2020
    Publication date: November 5, 2020
    Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
  • NANOPARTICLE COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20200297843
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Application
    Filed: March 18, 2020
    Publication date: September 24, 2020
    Inventor: Bruce McCreedy
  • Nanoparticle compositions and methods for immunotherapy
    Patent number: 10632193
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: April 28, 2020
    Assignee: NEXIMMUNE, INC.
    Inventor: Bruce McCreedy
  • NANOPARTICLE COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20190022215
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Application
    Filed: December 24, 2015
    Publication date: January 24, 2019
    Inventor: Bruce McCreedy
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20180214564
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20160129133
    Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
    Type: Application
    Filed: June 23, 2014
    Publication date: May 12, 2016
    Applicant: Nexlmmune, Inc.
    Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr